Abstract 2783
Background
Individual Care plans should be a co-creation between the patient and the health care provider, and should be updated by the contact nurse (CN) that is the patients’ main point of contact. Until recently the individual care plans for patients with Head & Neck cancer (H&N) in our region constituted of extensive written information in a ring binder and in addition a treatment plan from the medical records were printed and given to the patient. This quality improvement project aims to implement a digital and interactive version of the care plan, with a greater possibility to tailor information and increased availability. The implementation process contained of both the introduction of the digital tool (the care plan) and also new work processes for the nurses.
Methods
We followed the Plan Do Study Act approach. A clinical nurse leader together with the designer of the and an IT-technician worked together with the preparations (education, testing and risk assessment). All patients with H&N cancer could choose a standard care plan or the new digital format. The digital care plan was prepared by the CN. A person-centered approach was adopted for the digital care plans, with mandatory questions at the first visit with the CN; “What is important to you? - What is important that I know about you?”.
Results
30 % of chose the digital version of the individual care plan (n = 45) (patients were asked to choose either printed or digital). Patients and nurses were asked to give feedback on the content, usefulness and to suggest improvements. The first evaluation from the patients suggests improved patient participation and satisfaction. The CN stated that the digital care plan had advantages such as less time consuming, improved communication with the patients and supporting person-centered care. The patients can interact with the CN and may also use different symptom assessment scales and were involved during the whole implementation phase.
Conclusions
There is a potential for increased use of screening tools and systematic assessment of symptoms with the digital version of the IWCP. The mandatory question gave important information to the CN to consider. A designated nurse leader involved in the process is important during the implementation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Regional Cancer Center Stockholm Gotland.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract
1084 - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy
Presenter: Pauline Vaflard
Session: Poster Display session 3
Resources:
Abstract